We support clients through all phases of development and commercialization.
A Concept-to-Commercialization Viral Vector CDMO
Andelyn Biosciences is a gene therapy CDMO with deep expertise and experience in the development and production of viral vectors. With its origins including 20+ years of experience manufacturing viral vectors, Andelyn’s scientific expertise for development and characterization of gene therapies has led to GMP material being produced for over 75+ worldwide clinical trials and 450+ cGMP clinical batches. We support companies developing curative gene therapies for rare and prevalent diseases with plasmid manufacturing, process development, and GMP manufacturing capacity for both adherent and suspension processes up to 2,000L. An advanced digital model, quality system, full regulatory support, and supply chain vertical integration help accelerate the development and manufacturing of our clients' innovative therapies.
Clinical and Commercial Manufacturing
We provide our clients with a broad range of adherent and suspension-based viral vector and vaccine manufacturing services. Our cGMP facilities offer scalability up to 2000L and the reliability of platform processes and quality systems.
LEARN MORE
Process Development
We use a set of rigorous process development guidelines for process characterization, DoE and QbD principles to establish, implement and improve our clients’ viral vector and vaccine manufacturing processes.
LEARN MORE
Viral Vector R&D Production
We manufacture research and toxicology grade viral vectors that support preclinical studies, which include pilot, proof-of-concept, dose confirmation and IND-enabling toxicology studies.
LEARN MORE
Plasmid Manufacturing
We manufacture research and toxicology grade plasmids, which support pilot, proof-of-concept, dose confirmation and IND-enabling toxicology studies. In 2022, we will be offering Phase I/IIa plasmid manufacturing services.
LEARN MORE
Stay connected with Andelyn Biosciences.
Our Name
The name “Andelyn” was chosen to pay tribute to two brave young patients that participated in pivotal clinical trials that make today’s gene therapies possible.
Updates from Andelyn
News
November 20, 2023
Battelle, Andelyn Biosciences, and AmplifyBio Awarded Task Orders for Plasmid and Suspension AAV Vector Manufacturing and IND-enabling Studies from the National Institute of Neurological Disorders and Stroke (NINDS)
COLUMBUS, OH, Nov 20, 2023 – Battelle, Andelyn Biosciences, Inc., and AmplifyBio, have been awarded a new task order from the...
News
November 9, 2023
Andelyn Biosciences and The Ohio State University Collaborate for Pre-clinical and GMP Manufacturing of Novel Gene Therapies
COLUMBUS, OH, Nov 9, 2023 – Andelyn Biosciences, Inc., a pioneering and patient-focused cell and gene therapy Contract Development and...
News
October 20, 2023
Andelyn Biosciences and Purespring Therapeutics Partner to Manufacture Novel Gene Therapies for Kidney Diseases
COLUMBUS, OH, OCTOBER 20, 2023 – Andelyn Biosciences, Inc., a pioneering and patient-focused cell and gene therapy Contract Development and...
News & Media
June 22, 2023
Cell and Gene Therapy CDMO Andelyn Biosciences Celebrates Over 20 Years of Leadership and Innovation with Opening of New 180,000 Square Foot Manufacturing Headquarters
Columbus, Ohio – June 22, 2023 – Andelyn Biosciences, a pioneer in the development and manufacturing of cell and gene...
Our Employees Fuel Our Success
Andelyn is made up of an Inspired, Innovative and Compassionate team that contribute towards a rich company culture. We are always looking for great people who want to do great things.